0000000000303466
AUTHOR
T. Lotti
Randomised controlled study with cyproterone acetate (100 mg/die) versus Pygeum africanum (200 mg/die) in benign prostatic hypertrophy
A multi-centre comparative study was carried out on 143 patients with benign prostatic hypertrophy and reduced or no sexual activity. 74 patients were treated with a low dose of CPA (100 mg a day) and 69 with PYG (200 mg a day), administered orally and assigned randomly. The patients were evaluated at 4,12 and 24 weeks. Results showed a significant statistical difference in favour of the CPA treatment for almost all parameters (flow, post-micturitional residue, symptomatological score). There was a decrease in prostate volume, equal to 19.3% compared to the initial values, only in those patients treated with CPA who completed the treatment. Considerable improvement in nicturia and micturit…
Pruritus characteristics in a large Italian cohort of psoriatic patients
Background: Psoriasis (Ps) is a chronic systemic autoimmune disease associated with pruritus in 64–98% of patients. However, few modestly sized studies assess factors associated with psoriatic pruritus. Objective: To investigate factors associated with Ps pruritus intensity. Methods: Psoriasis patients 18 years or older seen in one of 155 centres in Italy between September 2005 and 2009 were identified from the Italian PsoCare registry. Patients without cutaneous psoriasis and those with missed information on pruritus were excluded. Results: We identified 10 802 patients, with a mean age 48.8 ± 14.3 years. Mild itch was present in 33.2% of patients, moderate in 34.4%, severe in 18.7% and ve…
Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry
Background: Some studies have shown that switching patients from one tumor necrosis factor (TNF)-alfa inhibitor to another may be beneficial when they have an inadequate response or an adverse event. Objective: We sought to assess the variables predicting the efficacy of the second TNF-alfa inhibitor in patients discontinuing the first TNF-alfa inhibitor. Methods: Data from all 5423 consecutive patients starting TNF-alfa inhibitor therapy for psoriasis between September 2005 and September 2010 who were included in the Italian Psocare registry were analyzed. Results: In 105 patients who switched to a second TNF-alfa inhibitor who had complete follow-up data, 75% improvement in the Psoriasis …